Comparative Pharmacology
Head-to-head clinical analysis: BELDIN versus CLARITIN D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BELDIN versus CLARITIN D.
BELDIN vs CLARITIN-D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1 receptor antagonist; inhibits histamine-mediated allergic and inflammatory responses.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
1 capsule (200 mg) orally every 12 hours.
One tablet (5 mg loratadine/120 mg pseudoephedrine sulfate) orally every 12 hours; do not exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal half-life: 8-12 hours (average 10 hours); prolonged in hepatic impairment (up to 24 h) and severe renal impairment (up to 18 h).
Loratadine: 8-14 h (mean 11 h); desloratadine: 17-24 h (mean 21 h). Pseudoephedrine: 4-8 h (mean 6 h), prolonged in alkaline urine.
Renal: 30-50% unchanged; hepatic metabolism: 50-70% (CYP3A4); biliary/fecal: 10-20%.
Loratadine: 40% renal (metabolites), ~40% fecal; desloratadine: 33% renal, 66% fecal. Pseudoephedrine: 70-90% renal unchanged, 1-2% biliary.
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination